The claim construction ruling reduces the likelihood of an adverse infringement finding that could disrupt Guardant360 and Guardant360 CDx sales. Monitor for any upcoming summary judgment motions or trial dates in the underlying case (1:25-cv-00263) that could further clarify infringement exposure. A settlement or cross-license may become more attractive for both sides following this ruling, which favors Guardant.
Price Chart
Executive Summary
The Court adopted Guardant Health's proposed construction for the key claim term "location on a [reference] genome," ruling it means "segment on a [reference] genome that is substantially identical to or substantially fully complementary to the subsequence of a tag associated sequence read corresponding to a species of nucleic acid molecule." This is a significant procedural win for Guardant, as the narrower construction favored by the defendant may limit the scope of the asserted patents in the ongoing infringement case over the Guardant360 blood tests.
Court Ruling Details
Key Facts
- Court adopted Guardant's proposed construction for 'location on a reference genome', finding it tied to the patent's definition of 'mapping'.
- Court rejected Cold Spring Harbor Laboratory's broader proposed construction for that term.
- Two other disputed terms from the '510 Patent received plain and ordinary meaning (no narrowing).
- The patents-in-suit (USPN 10,947,589 and 12,234,510) relate to methods for obtaining genomic copy number information via varietal counting of nucleic acids.
- Cold Spring Harbor Laboratory alleges Guardant's Guardant360 and Guardant360 CDx blood tests infringe these patents.
Financial Impact
No damages were awarded in this claim construction ruling. The financial impact is indirect—this is a probability shifter in the underlying patent litigation, which could impact Guardant's flagship liquid biopsy products (Guardant360 CDx revenue).
Risk Factors
- Claim construction is one step in a multi-step process—the case proceeds to the infringement and validity phases, where Guardant could still lose.
- Cold Spring Harbor Laboratory may appeal the claim construction ruling after final judgment.
- Parallel Inter Partes Review (IPR) proceedings at the PTAB remain pending and could independently invalidate the asserted patents regardless of this district court ruling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2ksvrfby-GH |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $163.18 $177.16 | ▲ +8.57% | ▲ +7.25% | $177.80 (+8.96%) |
Aug 13, 2026 7w ago | Insider Cluster | $157.21 $167.84 | ▲ +6.76% | ▲ +8.75% | $177.80 (+13.10%) |
Aug 13, 2026 7w ago | Insider Cluster | $157.21 $167.84 | ▲ +6.76% | ▲ +8.75% | $177.80 (+13.10%) |
Aug 11, 2026 7w ago | Insider Cluster | $165.11 $159.03 | ▼ −3.68% | ▼ −1.78% | $177.80 (+7.69%) |
Aug 11, 2026 7w ago | Insider Cluster | $165.11 $159.03 | ▼ −3.68% | ▼ −1.78% | $177.80 (+7.69%) |
Aug 6, 2026 8w ago | Insider Cluster | $168.48 $161.41 | ▼ −4.20% | ▼ −3.80% | $177.80 (+5.53%) |
Jul 30, 2026 9w ago | S-3ASR | $161.99 $161.49 | ▼ −0.31% | ▼ −3.29% | $177.80 (+9.76%) |
Jun 30, 2026 13w ago | Insider Cluster | $170.77 $144.07 | ▼ −15.64% | ▼ −13.45% | $177.80 (+4.12%) |
Jun 22, 2026 14w ago | 144 | $130.83 $148.07 | ▲ +13.18% | ▲ +12.02% | $177.80 (+35.90%) |
Jun 16, 2026 15w ago | Court Ruling | $127.34 $160.11 | ▼ −25.73% | ▼ −25.53% | $177.80 (−39.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access